Evidence map›Paper›PMID 33062721›Full record

ArticleJournal of immunology research2020

B7-H4 Inhibits the Development of Primary Sjögren's Syndrome by Regulating Treg Differentiation in NOD/Ltj Mice.

Xu Zheng, Qikai Wang, Xiang Yuan, Yingbo Zhou, Hui Chu, Guosheng Wang, Xiangpei Li, Yiping Wang, Li Wei, Li Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Sjögren syndrome: looking forward to the future.Therapeutic advances in musculoskeletal disease · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Xu ZhengDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.ORCID https://orcid.org/0000-0002-3244-4955
Qikai WangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Xiang YuanDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Yingbo ZhouDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Hui ChuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Guosheng WangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Xiangpei LiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Yiping WangWestmead Institute for Medical Research, University of Sydney, Westmead 2145 NSW, Australia.
Li WeiPharmacoepidemiology and Medication Safety Research Cluster, UCL School of Pharmacy, London WC1N 1AX, UK.
Li WangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.ORCID https://orcid.org/0000-0002-0486-7774
Xiaomei LiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.ORCID https://orcid.org/0000-0002-3103-2596
University of Science and Technology of China · CNThe University of Sydney · AUUniversity College London · GB

Funding

Medical Research Council G106/1249
6 · The paper itself

Abstract

backgroundThis study is aimed at exploring the role of B7-H4 in the pathogenesis of primary Sjögren's syndrome (pSS) in NOD/Ltj mouse.

methodsB7-H4 expression in salivary glands was examined by IHC, and lymphocyte infiltration was showed by H&E. Next, anti-B7-H4 mAb or immunoglobulin isotype was injected into NOD/Ltj mice. Cytokine levels were measured by quantitative RT-PCR, and immunoglobulins were measured by ELISA. T cell subsets were analyzed by flow cytometry. Last, we treated NOD/Ltj mice with B7-H4Ig and control Ig. CD4+Foxp3+ T cells were assessed by immunohistochemistry. Two-tailed Student's

resultsB7-H4 expression was remarkably reduced in salivary glands of NOD/Ltj mice at 15 weeks compared with the NOD/Ltj mice at 8 weeks. Anti-B7-H4 mAb treatment increased lymphocyte infiltration in salivary glands. Inflammatory cytokines including IL-12, IL-18, IL-1

conclusionsOur findings implicate that B7-H4 has a protective role for salivary gland epithelial cells (SGECs) and therapeutic potential in the treatment of pSS.

Indexed as

AnimalsCell DifferentiationCytokinesDisease Models, AnimalEpithelial CellsFlow CytometryForkhead Transcription FactorsHumansMiceMice, Inbred NODSalivary GlandsSjogren's SyndromeT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsV-Set Domain-Containing T-Cell Activation Inhibitor 1CytokinesForkhead Transcription FactorsFoxp3 protein, mouseV-Set Domain-Containing T-Cell Activation Inhibitor 1Vtcn1 protein, mouse

Identifiers

PMID33062721
PMCPMC7537676
OpenAlexW3088955100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.